AbbVie Inc. Earnings Recaps
Q2 2026
Aug 2, 2026
AbbVie's shares declined 2.5% following Q2 earnings despite beatings in revenue and EPS, reflecting investor caution likely tied to ongoing biosimilar erosion in HUMIRA and mixed segment performance that tempered enthusiasm.
Key takeaways
- Adjusted EPS came in at $3.65, $0.06 above guidance midpoint, with total net revenues nearly $17 billion, beating expectations by $300 million.
- Immunology sales grew 14.6% operationally to $8.8 billion, driven by SKYRIZI’s 24% growth and RINVOQ’s 23.7% growth; however, HUMIRA sales declined 36.1% due to biosimilar competition.
- Pipeline progress included FDA approval of Decnapaz and multiple European approvals (QLIPTA, Epkinly, Bowie, RINVOQ in derm conditions) with raised peak sales expectations for new indications.
- AbbVie announced acquisition of Apogee Therapeutics to deepen immunology pipeline, signaling focus on sustaining long-term growth.
- Despite revenue and earnings beats, the stock’s negative reaction suggests investor concerns around biosimilar impact and potentially cautious outlook on margin pressures or growth sustainability.
Q1 2026
Apr 30, 2026
Shares rose 6.9% following AbbVie’s first quarter, as revenues, EPS, and commercial performance in key franchises decisively beat expectations. Management announced an upward revision to full-year EPS guidance and highlighted strong execution across immunology and neuroscience portfolios. The positive market reaction suggests investors were focused on upside in top and bottom line performance, robust commercial momentum, and the confident guidance raise.
Key takeaways
- Adjusted EPS for Q1 reached $2.65, $0.07 higher than the mid-point of previous guidance; full-year adjusted EPS guidance was raised by $0.12.
- Total net revenues came in at $15 billion, exceeding internal expectations by $300 million and representing 12.4% sales growth.
- Skyrizi sales jumped 29.2% operationally to $4.5 billion, with leadership in key dermatology and IBD indications, while Rinvoq sales rose 20.2% to $2.1 billion.
- Neuroscience revenues grew 24.3% operationally to nearly $2.9 billion, surpassing internal forecasts.
- Strategic investments were cited, including $1.4 billion for a new manufacturing campus in North Carolina and ongoing R&D pipeline advances across immunology, obesity, and oncology.